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ABSTRACT 
 
FUNCTIONAL SIGNIFICANCE OF MTDNA CYTOSINE MODIFICATION TESTED BY 
GENOME EDITING 
By Jason M. Robinson 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
Virginia Commonwealth University, 2016 
Major Director: Dr. Shirley M. Taylor, Ph.D.  
Associate Professor of Microbiology and Immunology 
  
The field of epigenetics is gaining popularity and speed, due in part to its capability to 
answer lingering questions about the root cause of certain diseases. Epigenetics plays a crucial 
role in regulation of the cell and cell survival, particularly by cytosine methylation. It remains 
controversial if DNMT’s which facilitate methylation are present in mammalian mitochondria 
and what the functional significance they may have on modification of mitochondrial DNA. 
CRISPR-Cas9 technology enabled genome editing to remove the MTS (mitochondrial targeting 
sequence) from DNMT1 of HCT116 cells, purposefully minimizing effects on nuclear cytosine 
methylation, while exclusively impacting mitochondrial modification. Removal of the DNMT1 
MTS did not completely prevent the localization of this enzyme to the mitochondria according to 
immunoblot analysis. As well, deletion of the MTS in DNMT1 revealed only a small decline in 
transcription; not until removal of DNMT3B did we see a two-fold decrease in transcription from 
mitochondrial protein coding genes. No significant decline in transcription occurred when a 
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DNMT3B knockout also lost the MTS of DNMT1; this study is evidencing that DNMT3B is 
possibly the more significant methyltransferase in the mitochondria. Our aim from this study and 
future research is to clearly characterize which enzymes in the mitochondria are controlling 
cytosine modifications and to understand the mechanistic complexities that accompany cause 
and consequence of epigenetic modifications. 
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Chapter 1: Introduction 
Mitochondrial Overview 
If you have ever taken a high school biology class then you probably have heard that the 
mitochondrion is the powerhouse of the cell; broadly your teacher was trying to explain that 
mitochondria are responsible for generating most of your cells’ energy. In more scientific terms, 
mitochondria are able to convert ADP into ATP through the process of oxidative 
phosphorylation, thereby providing the cell with a source of usable chemical energy [1].  
The mitochondrial organelle is comprised of several components that have specialized 
function. The outer membrane encloses the entire organelle and contains integral membrane proteins 
called porins which are responsible for either actively or passively transporting proteins, depending 
on size, into the intermembrane space [1]. The inner mitochondrial membrane divides the 
mitochondrial matrix from the intermembrane space and contains import machinery with specific 
transport proteins that control metabolite pathways in and out of the matrix as well as ATP synthase 
and proteins involved in redox reactions [2].  The inner mitochondrial membrane is expanded by the 
cristae, invaginations that lead to additional surface area thus increasing the capacity to create ATP 
[2]. At the core of the mitochondrion is the matrix; this compartment is enclosed by the inner 
membrane and comprises the bulk of the mitochondrial mass. The matrix houses the mitochondrial 
DNA along with all the replication, transcription and translational machinery; it also contains free 
ribosomes and enzymes that facilitate the reactions that produce ATP during the Citric Acid Cycle 
and oxidative phosphorylation [2].  
Beyond energy production, the mitochondria also play pivotal roles in cell cycle regulation, 
cell growth, cell death, cellular signaling and differentiation. Mitochondria have been implicated in 
2 
 
variety of diseases from cardiac dysfunction to neuromuscular myopathies, and, as a result, are 
under intense scrutiny [3]. Due to recent findings, mitochondrial defects are finally being 
considered for their possible correlation in children with severe autism [4]. As mitochondria join in 
fundamental processes of cellular metabolism, research is starting to address the role of 
mitochondrial DNA in apoptosis, aging, and complex diseases such as ALS and cancer [3][5].  
Mitochondrial DNA 
MtDNA is a separate, organelle-specific genome; in humans, this genome contains 16,569 base 
pairs that encode 37 genes and lack noncoding regions [3]. These genes code for 2 rRNAs, 22 tRNAs 
and 13 proteins that are integral components in complexes of the electron transport chain. MtDNA is 
double-stranded and circular, comprised of a heavy outer strand and inner light strand [3][6] (Figure 1-
1). The outer strand is said to be heavy because it contains more purines than the inner lighter strand 
which contains more pyrimidines, which lack the extra ring structure that purines have [6].  
Although it is small in comparison to the nuclear genome (3 billion base pairs) the 
mitochondrial genome can contribute about 1% of the cell’s total DNA [7]; each mitochondrion 
contains 1 to 15 copies of mtDNA and human cells can house thousands of mitochondria [8]. 
However, despite having global influence from its energy production, and other critical roles along 
with having its own genome, the mitochondrion is nowhere near autonomous. Most mitochondrial 
proteins, including those that are involved in organellar transcription, translation, genome regulation 
and replication are transported to the mitochondria from beginnings in the nucleus [9]. 
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Figure 1-1. Diagram of the circular mitochondrial genome. Heavy strand with displacement 
loop is illustrated in dark blue and light strand in light blue. Genes that are labeled on the outside 
of the circle are associated with the heavy strand while genes on the inside are associated with 
the light strand and tRNA genes are depicted in red. Figure made by Lisa Shock 
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The Mitochondrial Displacement Loop (D loop) 
 The mitochondrial D loop carries both heavy (HSP) and light strand (LSP) promoters in 
close proximity to each other.  Immediately downstream of the LSP is the origin of replication 
for the H strand (OH) (Figure 1-1).  The D loop is believed to exist as a triple helical structure in 
complex with a short LSP-driven transcript [9], which acts as primer in replication of the heavy 
strand.  Super-high resolution microscopy studies [33,34] indicate that relatively few genomes 
within a given mitochondrion, possible only one, is engaged in replication at any time.  
Transcription from both HSP and LSP is believed to operate in a similar fashion: TFAM 
(Transcription Factor A Mitochondria) binds to each promoter, bending the DNA 180o through 
interaction of each globular domain with specific binding sites on each promoter.  The linker 
region of TFAM only assumes -helical structure through interaction with DNA (Taylor and 
Hackett, unpublished observations).  The DNA bend induced by TFAM brings its C-terminal 
domain in close proximity to the transcription start site, allowing it to recruit TFB2M 
(Transcription Factor B2 Mitochondria), which partially melts the promoter region, and 
mitochondrial RNA polymerase (PolRMT), and allowing initiation of transcription.  Each 
functional sequence domain required for replication and strand specific transcription are in very 
close proximity, leading to potential structural conflict in a genome attempting to carry out 
replication as well as transcription. 
Implications of multiple genomes within the mitochondrion 
 The mitochondrion, as mentioned, contains 1 to 15 copies (genomes) of mtDNA that 
code for 37 genes. Current research is leading to the hypothesis that the individual copies of 
mtDNA in the mitochondrion are not working on multiple functions at the same time, and that 
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each genome has specific instructions to carry out independent functional roles. It is thought that 
the genomes are partitioned into either replicating, transcribing or inert, packaged within TFAM-
coated nucleoids; the underlying mechanism controlling such partitioning is at present unknown.  
However, this hypothesis allows for the possibility that the cell can modulate its response to 
energy demands or stress by altering the balance of individual genomes engaged in each activity.  
The basis of this thesis is that modulation of functional roles among the mitochondrial genomes 
is controlled, at least in part, by epigenetic modification.  
Epigenetics 
 The field of research that is starting to answer lingering questions about the root cause of 
certain diseases is the field of epigenetics. Epigenetics is the study of heritable alterations in gene 
expression that are not caused by a change in DNA sequence [10]. Epigenetics plays a crucial 
role in regulation of the cell and cell survival, particularly by cytosine methylation [10]. It is an 
important balance of methylation that must be maintained in order for the cell to display a 
continual normal transcription. While not involved in any sequence change, epigenetic 
modifications such as methylation are directly related to how the transcriptional machinery can 
gain access to a DNA sequence and as a result controls which genes are transcribed or silenced 
[11].  
 Epigenetic regulation in the nucleus operates on several levels; DNA 
methylation/demethylation, histone modification, and assimilation of histone variants [12]. Our 
studies focus on DNA methylation since mtDNA lack histones [7]. Besides regulation of gene 
expression DNA methylation in the nucleus is involved in several significant processes, such as 
chromosomal X inactivation, imprinting, cellular reprograming, immune system development  
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http://missinglink.ucsf.edu/lm/genes_and_genomes/methylation.html 
Figure 1-2. Diagram of CpG Islands. An abundance of genes in the human nuclear genome 
possess upstream CG-rich areas, known as CpG islands. CpG islands, if methylated can represses 
gene expression; whether it is helpful or harmful is dependent upon the functionality of the gene. 
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and conservation of the genome integrity through guarding against endogenous retroviruses and 
transposons [13].  
 In eukaryotic nuclei, DNA methylation takes place on cytosine residues at the carbon 5 
position, principally in CG dinucleotides or CpG islands [13]. The main consequence of this 
methylation is an inhibitory tag to repress transcription [14]. The human genome was found to 
have roughly 56 million CpG sites, of which 60-80% are methylated [13]. Aberrant DNA 
methylation arrangements have been linked to some human malignancies; in comparison to 
normal tissue, tumor cells frequently have hypermethylation at promotor CpG islands resulting 
in gene silencing, while the majority of the genome is hypomethylated [13] (Figure 1-2). In 
contrast, normal genes predominantly display hypomethylation in the promotor region and 
elevated intensities of methylation in the rest of the gene.  The future of the epigenetic field is 
promising as modifications have shown to be reversible and are established as important 
therapeutic targets [15].  
DNA Methyltransferases 
Methylation is catalyzed by a family of enzymes termed DNA methyltransferases 
(DNMTs) [16]. S-adenosyl-methionine (SAM) is a cofactor that contributes a methyl group to 
the methyltransferase substrate, consequently methylating the C5 position of cytosine residues to 
produce 5-methylcytosine (5mC) [7] (Figure 1-3). It is a family of five genes that comprises the 
functional methyltransferase enzymes: DNMT1, DNMT2, DNMT3A/3B and DNMT3L [13]. 
 In the nucleus the initial and preserved pattern of methylation during embryogenesis is 
established by DNMT3A and 3B, otherwise called the de novo methyltransferases which show 
no preference for unmethylated and hemimethylated DNA [17]. DNMT3A and 3B are the only 
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active members of the DNMT3 group as DNMT3L is catalytically inactive [17], but assists 
DNMT3a and 3B in their substrate recognition. DNMT2 is inactive in methylating DNA but 
instead acts as an RNA methyltransferase [17]. DNMT3A and 3B are both essential for 
development; DNMT3A knockout in mice causes neonatal lethality, while DNMT3B knockouts 
die in utero [14]. Mutations in either DNMT3 are associated with a variety of disorders such as 
Tatton-Brown syndrome, a DNMT3A de novo mutation that is characterized by overgrowth and 
intellectual disabilities [18].  
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Figure1-3. DNA Methyltransferases. A) Methylation is catalyzed by DNA methyltransferases 
(DNMTs) on cytosines at the 5th position of the pyrimidine ring in CpG dinucleotides; S-
adenosylmethionine (SAM) is the methyl donor that converts cytosine to 5-methylcytosine. In a 
subsequent reaction, 5mC can be hydroxylated by the ten-eleven translocase (TET) family of 
methylcytosine dioxygenases. B) The parental strand (red)of DNA has its methylation pattern 
copied to the newly created strand (blue) during replication. This ensures that the gene 
expression of the parental strand is passed on and is the same as the daughter strand.  
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A problem arises during replication where one strand will initially lose its pattern of 
methylation during each cycle, and this is where DNMT1 comes into play (Figure 1-3). DNMT1 
maintains the existing pattern of methylation throughout replication and cell division [13]. 
DNMT1, unlike DNMT3A/3B, has a preference for hemimethylated DNA, and in addition is 
highly processive, being able methylate extensive runs without releasing its substrate DNA [13]. 
Like DNMT3B, DNMT1 is essential for development; DNMT1 knockouts in mice are 
embryonic lethal soon after gastrulation [14]. These DNMT knockout studies establish the vital 
nature of DNA methyltransferases and methylation in development and survival of mammalian 
cells. 
Mitochondrial DNA Methylation 
 It has been long established what the role of DNA methyltransferases are in nuclear 
DNA methylation and nuclear DNA methylation affects biological function; however the role 
and presence of DNMTs in mitochondria is a particularly controversial issue that has been at 
debate for almost half a century. There are disbelievers in the science community about mtDNA 
being methylated and will exclaim that previous research was excessively sensitive in nature and 
lacking reproducibility in their experimental methods. 
In 1971, DNA methyltransferase activity was detected in the mitochondria of a 
eukaryotic organism, suggesting the possibility that 5mC was present in mtDNA [19]. However, 
in those same years contrary evidence was presented stating the absence of 5mC in a mammalian 
model, consequently spawning the debate as to whether methylation exists in mitochondrial 
DNA [17].  
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Years later in 2004, researchers once again failed to observe mtDNA methylation in both 
gastric and colorectal cancers [20]. Although, they did divulge that frequencies of methylation 
less than 5% would not have been detected using their site-specific methylation restriction 
enzyme approach. This offers additional confidence to prior studies in 1984 that studied human 
fibroblasts and mouse fibroblastoids that identified methylation was present in mitochondrial 
DNA at 1.5-5% and solely in CpG dinucleotides [21] compared to mammals at 60-90%.  
 The pro-methylation side of the argument did not come back again until 2011 when 
researchers started to compile evidence for the cause. Novel methods were used by Shock et al. 
to establish the existence of 5mC in mtDNA; not only did these researchers display that 5mC is 
present in mtDNA but also demonstrated the presence of 5hmC, believed to be an intermediate in 
demethylation, and demonstrated that DNMT1 was the enzyme responsible for this modification 
[22].  
Possibly the most startling observation was that Shock et al. discovered a mitochondrial 
isoform of DNMT1 (mtDNMT1). The isoform has a conserved in-frame mitochondrial targeting 
sequence (MTS) with an alternative start site just upstream of the recognized start site for nuclear 
DNMT1 [22]. A mitochondrial targeting software program (MitoProt II) predicted with >90% 
probability that the targeting sequence would localize to the mitochondria.  They demonstrated, 
using confocal microscopy, that the mtDNMT1 MTS is able to deliver a heterologous protein 
(GFP) to the mitochondria [22]. 
Oxidative stress can cause the two principal regulators of mitochondrial biogenesis, 
proliferator-activated receptor c coactivator 1 (PGC1α) and nuclear respiratory factor 1 (NRF1) 
to activate and interact; this activation up-regulates several nuclear-encoded mitochondrial genes 
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[23]. Shock et al. was able to transiently transfect PGC1α, NRF1, or both together into HCT116 
cells to analyze levels of mtDNMT1 by means of immunoblot. Co-transfection of both regulators 
exhibited a fivefold upturn in total mitochondrial DNMT1, thus showing not only the presence of 
a DNA methyltransferase in the mitochondria but additionally demonstrating biological 
association to oxidative stress [22].  
Coincidently, the NRF1 binding site overlaps a p53 consensus binding site [24].  This 
tumor suppressor gene is known to control mitochondrial transcription, which lead Shock et al. 
to explore if mtDNMT1 mRNA expression is affected when p53 is deleted. They reported a 6-
fold increase in mtDNMT1 transcription in p53 null MEFs and HCT116 cells, which reinforces 
previous reports that p53 has a suppressive influence on expression of DNMT1 through specific 
DNA binding [23].  
Bisulfite modification transforms cytosine residues to uracil but leaves 5mC residues 
unaffected, and is an effective tool for studying DNA methylation in the genome [7]. Using this 
technique of bisulfite sequencing, a group reported that 5mC was restricted to the light strand of 
the D-loop region [16]. The same group was able to show expression of both DNMT1 and 
DNMT3B in mitochondria from HeLa cells, although, no other group has been able to show 
DNMT3B in the mitochondria [16]. 
Besides DNMTs that catalyze the conversion of cytosine to 5mC, there is also a family of 
enzymes that convert 5mC to 5 hydroxymethylcytosine (5hmC): ten-eleven-translocation (TET) 
enzymes [7]. The TET enzymes have been functionally identified in the nucleus but translocation 
of these proteins to the mitochondria remains controversial. The Taylor lab used 
immunoreactivity and confocal microscopy studies to show that Tet2 but not Tet1 localized to 
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the mitochondria; thus Tet2 is likely the enzyme responsible for the 5mC to 5hmC conversion 
[22]. This proof complements the belief that mtDNA is not only methylated but mitochondria 
contain the enzymes that allow for dynamic methylation and demethylation.  
Epigenetics as an essential control mechanism within mitochondria 
Previous work in the Taylor Lab has shown that increased methylation of mitochondrial 
genomes increases the affinity of TFAM for promoter sequences and increases transcription 
firing from both HSP and LSP in vitro and in vivo [25]. Epigenetics may therefore provide a 
mechanism whereby the individual genomes of the mitochondrion are partitioned into functional 
subgroups; investigating the patterns of methylation in individual genomes could characterize 
whether the mtDNA is actively replicating, being transcribed or at rest.  Generation of cell lines 
with specific and purposefully altered patterns of methylation will be the starting point of 
studying functional differences in genomes of the mitochondrion.   
 
CRISPR/Cas9 Genome Editing 
 Clustered Regularly Spaced Palindromic Repeats (CRISPR)/Cas9 is a bacterial immune 
system that has been adapted for use in multiple species and is rapidly becoming one of the most 
prevalent methods for genome editing. The system comprises a guide RNA (gRNA) which 
delivers an endonuclease, Cas9, to a specific site within the genome [26]. The gRNA contains a 
scaffold sequence which specifically binds the Cas9 endonuclease and delivers it to a 20bp target 
sequence [26] (Figure 1-4).  
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CRISPR/Cas9 can be used to generate site specific knockouts with a unique targeting 
sequence placed just upstream of a Protospacer Adjacent Motif (PAM); upon expression of the 
Cas9 endonuclease, it will bind the gRNA to form a riboprotein compound [27]. Upon binding, 
Cas9 will then undergo a conformational alteration which takes the molecule from an inactive 
state to an active one [27]. The complex is then able to cleave the target DNA resulting in a 
double-stranded break. The double-stranded break is then repaired by one of two pathways; non-
homologous end joining (NHEJ) or homology directed repair [26].  NHEJ is error-prone and 
sometimes results in small insertions or deletions (INDELS) in the target DNA; this can result in 
frameshift mutations leading to premature stop codons [27]. If possible, the ideal end result is a 
loss-of-function mutation within the desired locus.  Homologous recombination will occur at 
lower frequency if a repair oligo nucleotide, with homology to the sequences surrounding the 
break site are provided; this mechanism of repair is not error prone, and can be used to generate 
site specific mutations, insertions or deletions. 
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http://www.transomic.com/Products/CRISPR-Genome-Editing.aspx 
Figure 1-4. Diagram of CRISPR/Cas9 genome editing.  The Cas9 endonuclease will create a 
double stranded break.  There are two mechanisms of repair for the break: non-homologous end 
joining (NHEJ), which generates chance insertions or deletions at the cleavage site, or 
homologous recombination, which generates targeted mutations centered on DNA template.     
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Possible Genomic Editing of mtDNMTs  
As the interest in mitochondrial epigenetics grows and as the stack of evidence compiles 
that indicates mtDNA is methylated and that mtDNMTs are of biological significance, it is of 
interest to understand what the functional consequences are of mtDNMT loss. Mitochondria as 
mentioned before play pivotal roles in cell signaling and the cell cycle in addition to cellular 
respiration. Therefore, if DNMTs act in any way in the mitochondria as they do in the nucleus, 
then assessing their functional significance can lead to understanding of what happens when any 
of those cellular roles are defective.  
 Previous methyltransferase assays completed in the Taylor lab by Dr. Lisa Shock 
provided evidence that DNMT1 and DNMT3B are active in the mitochondria (Figure 1-5). 
These studies used mouse embryonic stem cells, previously generated by Li et al. [22], in which 
the catalytic domains of DNMT1, DNMT3A and DNMT3B, and combinations, were knocked 
out through gene targeting via homologous recombination. Mitochondrial lysates from these 
cells were used in in vitro methyltransferase assays [22].  Graphical analysis of this assay shows 
that DNMT1 and DNMT3B, but not significantly DNMT3A, are active in these cell lines.  
 Using methyltransferase assays and manipulating the mitochondrial isoform of DNMT1 
that the Taylor lab has developed an approach to test the functional significance of mtDNA 
cytosine modification. We used CRISPR/Cas9 to perform genome editing to construct innovative 
cell lines lacking the DNMT1 MTS as well as in combination with DNMT3B KO cell lines. 
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Figure 1-5. Methyltransferase assay. Previous work done by Dr. Lisa Shock in mouse 
embryonic stem cells. A Fluorometric EpiQuik DNMT Activity Assay Ultra (Epigentek) was 
used to measure activity in 10ug of protein from isolated mitochondria. Deletion of DNMT’s 
catalytic domain was accomplished through gene targeting and homologous recombination. 
Heterozygous and homozygous knockouts of DNMT1 were investigated along with DNMT3A 
and DNMT3B knockouts with TKO being a deletion of all three methyltransferases. This data 
displays that DNMT3B is active in the mitochondria.  
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We reasoned that upon removal of the MTS of DNMT1, methyltransferase activity in the 
mitochondria will decrease. In addition, we proposed that the removal of the MTS of DNMT1 in 
a cell lacking DNMT3B activity would reduce mitochondrial methyltransferase activity even 
further. We hypothesized that these changes in mitochondrial methyltransferase activity would 
lead to changes in levels of DNA modification and functional output of these organelles.  These 
reagents would be critical in determining whether mtDNA epigenetic modification is a 
mechanism whereby the functional partitioning of genomes within the organelle is dynamically 
controlled in response to the energetic needs of the cell. 
This hypothesis was tested by 
1) Methylation analysis using methylated DNA Immunoprecipitation (MeDIP), 
specifically within the mitochondria.  
2) Mitochondrial Purification and Immunoblot Analysis of DNMT levels.  
3) Mitochondrial Transcription analysis using RT-PCR.  
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Chapter 2: Methods 
Cell Culture 
HCT116 (CRL 1165) neomycin resistant wild-type, HCT 3BKO (gift from Dr. Bert 
Vogelstein, Johns Hopkins University) and genome edited derivative cell lines were grown at 
37oC in 5% CO2 in RPMI 1640 media (Gibco/Life Technologies) containing 10% fetal bovine 
serum. For all experiments performed, cells were fed 48 hours before harvest, trypsinized and 
replated 24 hours before harvest, identically to ensure consistency. DNMT1 is cell-cycle 
regulated so it was critical to harvest using this method to ensure that the bulk of the cells were 
in S-phase, where DNMT1 levels are at their peak.  
Cellular Fractionation 
To obtain purified mitochondria, crude whole cell lysates and cytosolic fractions, cells 
were harvested from 3x150mm dishes. The cells were washed two times with chilled 1x PBS, 
pH 7.4 while on ice. Cells were scraped from the dish and transferred to a pre-weighed 15ml 
conical tube (BD Falcon).  An aliquot of 10% percent from each cell line was separately 
reserved, pelleted and stored at -80oC for generation of whole cell lysate. The remaining cells 
were then pelleted and a whole cell pellet weight was acquired. Three mL of fresh mitochondrial 
homogenization buffer (10mM Tris-HCl, pH7, 0.25M sucrose, and 1mM EDTA, pH 6.8) 
containing 1 tablet complete protease inhibitors (Complete EDTA-free Protease Inhibitor 
Cocktail tablets, Roche) per 25ml buffer were added to resuspend cell pellets. The suspended 
cells were conveyed into a chilled 7ml glass dounce homogenizer and kept on ice for 5 minutes 
to permit cells to swell in the hypotonic homogenization buffer. Three series of douncing (15 
down and up strokes per series) were performed, each followed by a 2,200rpm centrifugation for 
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5 minutes at 4oC. The post-nuclear supernatant that contained the cytosolic and mitochondrial 
fractions were saved after centrifugation. The remaining unbroken nuclear pellet was 
resuspended and subjected to douncing until three series were complete. The pooled post-nuclear 
supernatant was again centrifuged to pellet any contaminating nuclear fraction and collected in a 
14ml round-bottom tube (BD Falcon). The supernatant was then centrifuged at 9,000 rpm for 15 
minutes at 4oC to obtain a crude mitochondrial pellet with the supernatant retained to prepare the 
cytosolic fraction.  
The mitochondrial fraction was further purified by taking the crude mitochondrial pellet 
and adding 1mL of homogenization buffer with protease inhibitors and centrifuging for 9,000 
rpm for 15 minutes at 4oC two times to wash the pellet. The pellet was then washed again as 
before but without protease inhibitors and resuspended in a volume 10 times the pellet weight in 
Tyrpsin Digestion Buffer (250mM Sucrose, 2mM EDTA, .5mM EGTA, 10mM HEPES-KOH 
and 1mM DTT). Typsin-EDTA (Gibco) 100µg/mL was added to reach a final concentration of 
10µg/mL. Samples were held at 21oC for 20 minutes with intermittent gentle inversion to mix 
contents. After incubation, bovine trypsin inhibitor (Sigma) 1mg/mL was added to a final 
concentration of 10µg/mL; tubes were inverted to mix and placed on ice for 10 minutes. The 
contents were then centrifuged at 9,000 rpm for 10 minutes at 4oC to pellet intact mitochondria. 
The pellet was then washed twice with 1mL of homogenization buffer with protease inhibitors 
and 10µg/mL bovine trypsin inhibitor and centrifuged as before. The final mitochondrial pellet 
was resuspended and vortexed in SDS Lysis Buffer at 10 times the pellet weight and stored at -
20oC.  
The cytosolic fraction was further purified by acetone precipitation. Acetone was added 
to cytosolic fraction at 4x volume and held at -20oC overnight. Tube was then centrifuged at max 
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speed for 15 minutes at 4oC. Cytosolic pellet was then separated from the supernatant and air-
dried for 10 minutes. The cytosolic pellet was then resuspended in 100µl SDS Lysis Buffer and 
stored at -20oC.  
The whole cell lysate was prepared by centrifuging 2500rpm at 4oC for 5 minutes and 
PBS removed. The pellet was then resuspended in SDS Lysis Buffer at 7.5x volume and passed 
through a 21G needle to obtain a homogenous lysate, and then stored at -20oC.  
Immunoblotting 
Protein concentration for lysates was determined using a Bradford assay. A standard 
curve was made with known concentrations of BSA and was used to determine the protein 
concentration of the protein lysates. The assay was quantified using a Genesys 10uv 
spectrophotometer (Thermo).  Samples were loaded onto 4-20% SDS-PAGE precast gels. 30µg 
of protein were loaded for whole cell lysate comparisons. 75µg of whole cell lysate, 25µg of 
cytosolic lysate and 18µg of mitochondrial lysate were loaded for subcellular fractionation 
comparisons, to approximate loading of equal cell equivalents. The required volume of lysate 
was then mixed with an equivalent volume of Laemmli buffer+ 5% BME. Samples were then 
boiled for 10 minutes without placing on ice prior to being loaded into a gel. Samples were 
loaded alongside 6 μL of Precision Plus Dual Color ladder (BioRad). The gels were 
electrophoresed at 120V for ~1 hour in 1x running buffer (25mM Tris base,0.1% SDS, 250mM 
glycine in 1L total volume). Resolved proteins were then transferred to an Immobilon-FL PVDF 
membrane in transfer buffer, consisting of 200mL methanol, 700mL ddH2O and 100 ml 10X 
transfer buffer (16.879g TrisHCl, 144.134g Glycine, 10g SDS, 17.299g Tris Base). The gel was 
rinsed with ddH2O and transferred to the 1x transfer buffer for 15 minutes at 4°C for 
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equilibration. The membrane was activated in methanol for ~1 minute and washed with ddH2O 
for ~1 minute prior to being transferred into 1x transfer buffer for 15 minutes at 4°C for 
equilibration. The transfer apparatus (gel, membrane, transfer plate, sponges, Whatman paper) 
was carefully assembled and placed in the transfer box with 1x transfer buffer at 4oC and transfer 
was carried out for 1 hour at 100V. After the transfer was complete the apparatus was 
disassembled and the membrane was washed for 1 minute with ddH2O and then activated in 
methanol for 30 seconds. The activated membrane was then ready to be checked for a positive 
transfer with Ponceau stain (Bio-Rad); 2 minute soak then visualize when slowly rinsing off with 
ddH2O. The washed membrane was then placed in StartingBlock T20 (ThermoFisher) overnight 
at 4oC with shaking. The appropriate primary antibody diluted in StartingBlock T20 was then 
added to the membrane with light shaking at room temperature for 1 hour. After primary 
antibody the membrane was washed three times with 1x TBS-T (0.5M Tris-HCl, 2.7mM KCl, 
0.14M NaCl and 0.1% Tween 20) with heavy shaking for 15 minutes. The membrane was then 
lightly shaken in the appropriate secondary antibody diluted in StartingBlock T20 for 1 hour at 
room temperature. After the secondary antibody incubation the membrane was washed again in 
1x TBS-T as before. The membrane was then blotted dry to remove excess buffer and 
SuperSignal West Dura (Pierce) was added so the blots could be developed on a Li-Cor Odyssey 
system.  
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Table 1: List of antibodies and optimal conditions. 
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CRISPR/Cas9 Genome Editing 
In order to create a frame-shift mutation within the MTS a single guide RNA was created, 
which, along with Cas9 endonuclease should cause small insertions or deletions (indels) through 
the error-prone non-homologous end joining (NHEJ) repair mechanism. Several potential 
gRNAs were screened for potential off-target cleavage events by blast search and using the MIT 
gRNA and off-target prediction tools found at www.crispr.mit.edu/.  The selected gRNA is 
highlighted in yellow in Figure 2-1. 
gRNAs were synthesized by extension of overlapping oligonucleotides [33] (guided 
literature) and inserted into the gRNA expression vector by Gibson Assembly according to the 
manufacturers protocol (New England Biolabs).  Ligation reactions were transfected into 
competent DH5a and clones were screened by DNA sequence analysis. 
HCT116 and its derivatives (3BKO and DKO) were plated at 1x106 cells per well in a 6-
well plate.  Transfections were carried out using polyjet lipid based transfection reagent 
(SignaGen Scientific) using 2ug DNA and 3uL polyjet per well.  Transfection efficiency was 
determined to be >80% based on transfection of control wells with pMaxGFP.  To minimize 
prolonged expression of Cas9 endonuclease, cells were co-transfected with a puromycin 
expression vector (pLVTHMpuro) and transfected cells selected by resistance to 1ug/ml 
puromycin.  Cells were replated into 150mm dishes 48 hours post-transfection, and selection was 
applied 24 hours later.  Additional controls included untransfected cells, and cells transfected 
with pLVTHM alone. 
Approximately 10 days after transfection, individual colonies were picked using 
polyester-tipped sterile swabs and plated into 48well plates.  To generate replica plates, clones 
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were individually released with trypsin-EDTA (Gibco) and diluted into 2 additional plates.  After 
growth for 5-7 days, one plate was cryopreserved at -800C in 90% fetal bovine serum 10% 
DMSO, one plate was harvested for DNA preparation and PCR-based screening, and one was 
maintained with bi-weekly medium changes.  
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Figure 2-1. Genomic sequence surrounding exon 1 of the human DNMT1 gene.  
Selected gRNA is highlighted in yellow.  The screening amplicon lies between sense PCR 
primer (green) and antisense primer (red).  Start ATG codons are indicated in yellow and 
the mitochondrial targeting sequence is in bold italics.  The published transcription start site 
for the nuclear isoform begins at capitalized nucleotides 
cttggtactagctacaaattctgtgtatactcaagattttctagagtaggtgcaattaccccgtttta
cagatgaggacacagaggctgagccgtagtgacccacctaaggtcgtatagccagcaaatagatggag
gttggattggaactgag 
gactttactcaagggctctcacaaacccttgggggcttctcgctgctttatccccatcacacctgaaa
gaatgaatgaatgaatgcctcgggcaccgtgcccacctcccagcaaaccgtggagcttggacgagccc
actgctccgcgtggggggggtgtgtgcccgccttgcgcatgcgtgttccctgggcatggccGGCTCCG
TTCCATCCTTCTGCACAGGGTATCGCCTCTCTCCGTTTGGTACATCCCCTCCTCCCCCACGCCCGGAC
TGGGGTGGTAGACGCCGCCTCCGCTCATCGCCCCTCCCCATCGGTTTCCGCGCGAAAAGCCGGGGCGC
CTGCGCTGCCGCCGCCGCGTCTGCTGAAGCCTCCGAGATGCCGGCGCGTACCGCCCCAGCCCGGGTGC
CCACACTGGCCGTCCCGGCCATCTCGCTGCCCGACGATGTCCGCAGGCGgtaggtaccatggggggga
acacggactcagggggacaggcagggcgctgggtggggggtcgcttcccctcggggtggccggtggcc
gctgctgacagacgggcgcgcatgcgtggggtggtgcggcgcgcagcggcagttggcgcgggcagggt
ggcacttccggtcgcgcgtgcccgggctgtttggcgccaaaatggaccgtggattccc 
ccgtagctccctggtggctagaaactaggcggggtgggggttctcttttgatccccaaatacagcaag
ctttgggttcgtttccggggtccccttcttcaagcagcggtgggccgggctcttgactccagcttggt
cgcacaggaagtgggcagcccgcggccaacggacacccctcgggcaccggcacttcggcctccacttc
cggtgtccggcccggtccccgggggcgcttctgtggtggggggtccctcagtgcctttcccccaaagc
tgtgc 
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DNA Extraction and PCR Screening of genome edited cell clones 
To select DNA clones for downstream application from CRISPR/Cas9 genome editing, 
DNA was extracted using MyTaq Extract-PCR Kit (Bioline). An individual well from a 48-well 
plate was harvested for each clone, using 50ul of MyTaq Extract buffer. Lysates were transferred 
to a 1.5ml microfuge tube and vortexed. The lysates were incubated for 5 minutes at 75oC with 
intermittent vortexing then deactivated by heating to 95oC for 10 minutes. Remaining cellular 
debris was pelleted and the supernatant transferred to a new 1.5ml microfuge tube. The 
supernatant was then diluted 10-fold in HPLC H2O for PCR analysis.  
PCR reactions consisted of 1µl of diluted template, .5µl of each forward and reverse primers 
(15M), 12.5µl of My Taq HS Red Mix and 5.5µl of HPLC H2O to total 25µl. The reactions 
were amplified in a Mastercycler (Eppendorf) and cycling conditions were as follows: 95oC 
initial denaturation phase for 3 minutes, 95oC denaturation phase for 15 seconds, 56oC (primer 
dependent) annealing phase for 15 seconds and a 72oC extension phase for 20 seconds and held 
at 4oC as needed.  
 To screen for positive clones in genome edited samples a T7 endonuclease assay was 
performed. T7 endonuclease will recognize and cleave mismatches in a imperfectly matched 
DNA duplex.  The reactions were all performed in a Mastercycler (Eppendorf) and set up as 
follows: 13µl of HPLC H2O, 2µ NEB Buffer 2 and 3µl of wild-type HCT116 amplicon. 
Reactions were performed in duplicate so that a side by side comparison could be done between 
wild-type and genome edited samples; 2µl of HPLC H20 were added to wild-type and 2µl of 
genome edited sample were added to one of the samples for the duplicate reaction. The samples 
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were placed in the Mastercycler for a round of hybridization with cycling conditions as follows: 
initial denaturation at 95oC for five minutes, gradual annealing of -2 ℃ /s to 85 ℃ then -0.1 ℃/s 
to 25 ℃ and held at 4oC. T7 endonuclease (NEB) (0.1units/sample) was added to each reaction 
carrying a mixture of wt and genome edited amplicon, and the reactions were incubated at 37oC 
for 15 minutes in the Mastercycler.  Products (20ul) were mixed with 1 µL 10x DNA loading 
dye and resolved on a 1% agarose gel in 1x TAE with EtBr at 80V for 30 minutes. The gels were 
viewed with a FluorChem Sp (Alpha Innotech). A cleaved band on the gel would indicate a 
mismatch in DNA indicative of positive genomic editing. Samples with a cleaved band were sent 
out to be sequenced (Eurofins) to determine specific mutations generated.   
Each clone identified to carry mutations likely to disrupt the MTS was analyzed using 
Mitoprot II to increase confidence that the enzyme would not translocate to the mitochondria.  In 
some instances, the indel generated a new ATG codon with a measurable probability of 
translocation to the mitochondria.  These clones were not analyzed further. 
Sub-cloning to validate purity of individual genome edited clones. 
Clones carrying indels that produced the desired interruption of the mitochondrial 
targeting sequence were expanded, cryopreserved, and sub-cloned to ensure purity of the cell 
line.  Cells were plated at a density of 100 cells/100mm dish, and individual colonies were 
picked 10 days after plating as described above.  Each clone was cryopreserved and analyzed for 
the same indel as the parent clone.  Ten sub-clones were analyzed for each parental clone and 
only those for which all ten showed identical sequences were maintained for further analysis. 
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RNA Isolation 
 RNA was isolated by harvesting HCT116 cells from one ~80% confluent 60mm dish. 
The cells were then lysed in 1mL TRI Reagent (Applied Biosystems) and incubated at room 
temperature for 5 min for nucleoprotein complexes to dissociate. 200µL of chloroform was 
added, samples were vortexed and incubated at room temperature for 10 minutes. The samples 
were then centrifuged at 12,000 x g for 10 minutes at 4oC and the top aqueous phase containing 
RNA was transferred to a new tube. 500µL of isopropanol was added, samples were vortexed 
and incubated at room temperature for 5 minutes. After incubation the samples were centrifuged 
at 12,000 x g for 8 minutes at 4oC and the supernatant was discarded leaving a precipitated RNA 
pellet. To wash the pellets 1mL of 75% ethanol was added; pellets were centrifuged for 5 
minutes at 7,500 x g and the ethanol removed. The remaining RNA pellet was then air dried for 5 
minutes and resuspended in 100µL RNase-free H2O. 
 RNA was further purified by removal of genomic DNA by DNase I (RNase free) (Life 
Technologies). 10X DNase I Buffer was added to the RNA sample to make a 1X concentration 
followed by adding 1µL DNase I  per 1µg DNA with a 30 minute incubation at 37oC. After the 
incubation period the RNA sample was heated to 75oC for 10 minutes to inactivate the DNase I.  
 The RNA was analyzed for contamination by agarose gel electrophoresis. ~1µg of RNA 
solution was heated to 70oC for 1 minute and placed on ice before loading. The samples and a 
1kb + Ladder (Invitrogen) were resolved on a 1% agarose gel in 1x TAE with EtBr for 50 
minutes at 60V. The products were then analyzed for degradation (smearing) and band intensities 
on a FluorChem Sp (Alpha Innotech). 
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First Strand Synthesis 
 First strand cDNA was created with the SuperScript ™ III First-Strand Synthesis System 
for RT-PCR (Life Technologies). All components used were briefly mixed and centrifuged 
before being combined in a .5mL tube. Total RNA (5μg) was mixed separately with either 1µL 
2µM ATP6 forward, ATP6 reverse primers or 1μL random hexamers, 1μL (10 mM) dNTP mix, 
and HPLC H2O to a total volume of 10µL. Negative no template (2µL HPLC H2O) control and 
positive Hela (5µg) controls were run as well. The reactions were heated to 65oC for 10 minutes 
and then placed on ice for 1 minute. The cDNA synthesis mix was prepared by adding 80μL of 
10X RT buffer, 160µL of 25mM MgCl2, 80µL of 0.1M DTT, 40µL of RNaseOUT™ (40 U/µl) 
and 40µL of SuperScript® III RT (200U/µL). 10µL of cDNA Synthesis Mix was added to each 
RNA/primer reaction and gently mixed and centrifuged. The reactions were incubated for 50 
minutes at 50oC followed by termination of the reaction at 85oC for 5 minutes and then chilled 
on ice. The reactions were collected by centrifugation, 1µL of RNase H was added and samples 
were incubated at 37oC for 20 minutes. For long term storage, reactions were stored at -20oC.  
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    Table 2: Human Mitochondrial Primer Sequences.  
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RT-PCR 
 cDNA synthesis was carried out with three different priming methods.  ATP6 forward 
and ATP6 reverse cDNA primers allowed measurement of independent, strand-specific 
transcription from each mitochondrial promoter (HSP and LSP).  For heavy strand transcription, 
PCR primers located within the 16s, ND1 and Cox1 open reading frames (ORFs) were used in 
separate qPCR reactions.   For light strand transcription, ND6 primers were used. Nuclear genes 
encoding GAPDH and Actin were used to normalize RT-qPCR data, using cDNA synthesized 
with random hexamers. The reactions consisted of 10µL SsoFast Universal SYBR Green 
SuperMix (BioRad), 0.75µL each of forward and reverse primers (10mM), 7.5µL HPLC H2O 
and 1µL of cDNA template for a total volume of 20µL. The reactions were assembled in a 96-
well plate and processed on a BioRad DNA Engine Peltier thermal cycler with a built-in 
Chromo4 Real-Time Fluorescence Detector. Cycles consisted of a 30 second initial denaturation 
phase at 98°C, a 10 second denaturation phase at 98oC and a 20 second annealing phase based on 
the Tm of the primers (56°C- 64°C) with the last three steps repeated for a total of 40 cycles.  A 
melting curve was made after cycling by changing the temperature from 65°C to 90°C and read 
and recorded every 1°C. Final data were analyzed using the OpticonMonitor3 program.    
Methylated DNA Immunoprecipitation 
 The effect of genome editing on mitochondrial cytosine modification was measured by 
Methylated DNA Immunoprecipitation (MeDIP), using antibodies specific for 5mC and 
5OHmC. To obtain methylated and hydroxymethylated DNA samples HCT116 cells were 
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harvested from 2-80% confluent dishes. DNA extraction of the cells was performed using a 
DNeasy Blood and Tissue Kit (Qiagen) 
 The DNA samples were then purified by phenol chloroform extraction and ethanol 
precipitation. An equal volume of Phenol:Chloroform:IAA (25:24:1) was added to each sample, 
vortexed and centrifuged at 16,000rpm for 5 minutes at 4oC.  The aqueous phase was transferred 
to a fresh tube and an equal volume of chloroform was added to each sample, vortexed and 
centrifuged as before. Again, the aqueous phase was transferred to a fresh tube and 1/10 volume 
of 3M sodium acetate along with 10µL of glycogen was added and mixed. Ethanol was added at 
3X volume, samples were mixed and incubated at -80oC for 20 minutes. After incubation 
samples were centrifuged at 14,000rpm at 4oC for 30 minutes. The supernatant was removed and 
500µL of 70% EtOH was added to the pellet and vortexed. Again, the samples were centrifuged 
at 14,000rpm at 4oC for 30 minutes and the supernatant was removed. The pellets were allowed 
to air dry for 10 minutes and resuspended in 200µL HPLC H2O. 
 The purified DNA was then sonicated using a Diagenode Biorupter water bath sonicator 
for 2-15 minutes cycles of 30 seconds on and 30 seconds off at the highest setting. 10µL from 
each round of sonication plus a non-sonicated aliquot were retained from each sample and 
resolved on a 1% agarose gel; this gel is a check for a 200-700bp smear indicative of proper 
sonication.  
 To set up the IP, 4µg of purified and sonicated DNA per antibody was diluted in TE 
buffer (10mM Tris, 1mM EDTA) to a total volume of 450µL. The samples were then denatured 
in boiling water for 10 minutes, directly cooled on ice for 10 minutes and 0.5uL of 10X IP buffer 
(1.4M NaCl, 0.5% Triton X-100, 100mM NaPO4 pH 7.0) was added in addition to 2µg of 5mC 
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rabbit monoclonal (Active Motif #61255), 5OHmC rabbit monoclonal (Active Motif #39769), or 
IgG control rabbit monoclonal antibody (Millipore #12-370). The tubes were then incubated 
overnight at 4oC while rotating. To pre-block the Protein G Sepharose 4 Fast Flow (GE 
Healthcare), 30µL per IP sample were centrifuged at 4,500 rpm for 5 minutes at 4oC and the 
ethanol supernatant was removed. 400µL 0.1% PBS-BSA (10mg BSA, 10mL PBS pH 7.4) was 
added to wash the beads and this wash was repeated three times. After the third wash the pelleted 
beads were resuspended in an equal volume 1X IP buffer to make a 50% slurry. To block the 
beads 5µg of BSA and 5µg sonicated Lambda DNA (NEB) were add per 30µL of slurry and 
rotated at 4oC overnight. At the end of the overnight incubation the beads were washed three 
times as before and resuspended in 1X IP buffer. To the DNA samples with antibody 
approximately 30µL of beads were added to the tubes and rotated for 2 hours at 4oC. At the end 
of the incubation the beads were centrifuged at 4,500rpm for 5 minutes. The supernatant from 
this last step was saved in fresh tubes as inputs for qPCR; the beads were further washed three 
times with 1X IP buffer and rotated at 4oC for 10 minutes. After the third wash the pelleted beads 
were resuspended in 250µL Proteinase K digestion buffer (10mM EDTA, 0.5% SDS 50mM, Tris 
pH 8.0) and 3.5µL Proteinase K (20mg/mL stock). The tubes were then incubated in a shaking 
water bath to prevent sedimentation at 50oC for 3 hours. After the incubation the beads were 
centrifuged at 4oC for 5 minutes and the supernatant that now contains the DNA retained. The 
DNA samples were then subject to another phase of purification by phenol/chloroform extraction 
and ethanol precipitation. The exact steps were followed as before except the last step in which 
the DNA was resuspended in 75µL TE buffer not HPLC H2O. 
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End point PCR 
 End point PCR was executed using HotStarTaq Master Mix (Qiagen). Each reaction consisted of 12.5 
µL of HotStarTaq, 1 µL of forward and reverse primers (10 µM) and 9.5 µL of HPLC H2O as a master 
mix; 19µL of master mix were dispensed into individual wells per reaction and 1 µL of cDNA was added 
to each appropriate well. The reactions were run in a Mastercycler (Eppendorf). Reactions were held at 
95°C for 5 minutes prior to cycling. Cycles entailed a 30 second melting phase at 95°C, a 30 second 
annealing phase based on the Tm of primers (56°C-64°C), and a 1 minute extension phase at 72°C for a 
total of 25 cycles to assess the quality of the IP prior to qPCR. When cycling was complete the reactions 
were run at 72oC for 5 minutes and held at 4oC as long as needed. Products were resolved on a 1% 
agarose gel in 1x TAE with EtBr. 10 µL of the product were mixed with 1 µL 10x DNA loading dye and 
ran at 80V for 30 minutes. The gels were viewed with a FluorChem Sp (Alpha Innotech) imager. 
qPCR  
qPCR was set up using QuantiNova SYBR Green PCR mix (Qiagen). A master mix was constructed 
containing 12.5 µL of QuantiNova SYBR Green PCR mix, 1 µL of 10 µM forward and reverse primers 
each and 9.5 µL of HPLC H2O per reaction. 19 µL of master mix were pipetted into each appropriate well 
of a 96 well plate with 1 µL of cDNA added to each appropriate reaction. Reactions were each performed 
in triplicate. The plate was processed on a BioRad DNA Engine Peltier thermal cycler with a built-in 
Chromo4 Real-Time Fluorescence Detector. The samples were held at 95°C for 5 minutes prior to 
cycling. Cycles consisted of a 30 second melting phase at 95°C, 30 second annealing phase based on the 
Tm of the primers (56°C- 64°C) and a 1 minute extension phase at 72°C for a total of 40 cycles.  A 
melting curve was produced after cycling by changing the temperature from 65°C to 90°C and read and 
recorded every 1°C. Final data was examined using an OpticonMonitor3 program. 
36 
 
Chapter 3: Results 
Targeted Mutation of The Mitochondrial Targeting Sequence of DNMT1 using 
CRISPR/Cas9 Genome Editing.  
 Guide RNAs were developed to target close to the published mitochondrial transcription 
start site of DNMT1 (Fig. 3-1), with the goal of introducing small insertions or deletions that 
would disrupt the reading frame of the targeting sequence without disrupting nuclear DNMT1 
expression. DNA was extracted from individual clones that were genome edited by 
CRISPR/Cas9 using MyTaq Extract and PCR amplified using DNMT1 primers to initiate the 
screening procedure for successful editing (Fig. 3-2); expected PCR products of wild type and 
genome edited HCT116 cells were 630 bp using these DNMT1 primers.  All clones illustrated 
(Figure 3-2) were positive for DNMT1 PCR amplification, however in the 48-well plate that was 
screened this was not universally the circumstance.  Clones that failed to produce a visible band, 
usually because of poor growth, were discarded. PCR amplicons where then tested for 
CRISPR/Cas9 induced mutation using the T7 endonuclease assay to detect mismatches between 
wild-type and putative mutant DNA. Equal amounts of wt and genome edited clone DNA were 
mixed, denatured and allowed to reanneal.  Annealed PCR products incubated in the absence and 
presence of the T7 endonuclease, and the T7 assay products were resolved on an agarose gel 
(Fig. 3-3); Predicted 630bp bands were apparent for wild-type and wt/genome edited clones 
without endonuclease. Samples where apparent digestion by the T7 endonuclease took place 
produced products at 400 and ~150-200 base pairs. Samples that had these lower bands indicated 
a mismatch between wt and genome edited sample, these were sent out for sequencing. 
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Figure 3-1. Partial human DNMT1 sequence upstream of Exon1 encoding mitochondrial 
targeting sequence. Upstream of the published nuclear DNMT1 start site (ATG3) there are two 
additional potential start sites (ATG1, ATG2). Guide RNA (red underline) was designed 
upstream of ATG3 within the additional 101 in-frame amino acids that encode the MTS (red 
lettering) to disrupt mtDNMT1 without affecting the nuclear DNMT1 protein (green lettering).  
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Figure 3-2. Verification of mtDNMT1 DNA amplicon. Agarose gel electrophoresis of PCR 
assay performed to verify predicted 630bp fragment using DNMT1 primers. Lane 1, 1kb+ 
Ladder (Invitrogen); 2, positive control amplicon using wt DNA; 3-10, genome edited 
amplicons; 11, negative (no template) control. 
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Figure 3-3. Verification of mtDNMT1 mutant construct. Agarose gel electrophoresis of T7 
endonuclease assay illustrating DNA amplicons run in parallel with DNA amplicons with T7 
enzyme. In samples containing mismatches between wt and mutated DNA, the 630bp predicted 
DNMT1 fragment (blue arrow) was digested to ~450 and ~150bp (red arrows) with T7 
endonuclease fragments. Clones of prospective genome editing were selected by band intensity 
difference between amplicon and amplicon with T7 enzyme along with digested smaller 
fragments. Samples C3-C8 were selected for sequencing due to this criteria.  
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Figure 3-4. Initial sequencing displayed novel stop codon. Sequence results from Eurofins 
International of DNA amplicons from genome edited HCT116 cell line. Seq_1 is of HCT116 
wild-type to contrast Seq_2 which is genome edited. The mutated DNA carries a 17 bp deletion 
across the Guide RNA (grey highlight), generating a new stop codon (red). ATG 2 (green 
highlight) to novel stop codon (red) alters and potentially creates an inoperable MTS.  
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Initial sequence results revealed premature stop codon.  
The guide RNAs’ specific targeting allowed for the Cas9 endonuclease to create a 
cleavage site shortly after the transcriptional start site of mtDNMT1, thus leaving the nuclear 
start site for DNMT1 unaffected. Cellular error prone repair mechanisms (NHEJ) frequently 
results in small insertions or deletions around the cleavage site.  In the example shown in Fig. 3-
4, a 17 bp deletion generates a premature stop codon upstream of the nuclear start ATG, resulting 
in a truncated protein from ATG1 or 2, and presumably a nonfunctioning MTS.  
Immunoblot analysis of DNMT1 revealed residual mitochondrial presence of genome 
edited DNMT1.  
Immunoblotting was used to analyze levels of DNMT1 in whole-cell, cytosolic and 
mitochondrial fractions from HCT116 wildtype and two different HCT genome edited samples. 
Stringent controls were in place to ensure that cell fractionation was complete, with absence of 
contamination from other fractions. An antibody for voltage-dependent anion channel (VDAC) 
located on the outer membrane of the mitochondria was used to certify equal loading. Anti-
Histone H3 (tri methyl K4) (H3K4me3) antibody should only detect this nuclear protein in the 
whole-cell lysate fraction; presence in any other fraction is indicative of nuclear contamination. 
Tubulin is a globular protein that polymerizes into microtubules; it is absent from the 
mitochondria and its expression should only be found in whole-cell lysate and cytosolic fractions 
with its antibody. To note: the tubulin antibody even at exceptionally low concentrations is still 
an extremely potent antibody and trivial amounts of detection in the mitochondrial fraction 
should be carefully considered in combination with other controls as a suitably uncontaminated 
fraction.  
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 Over the course of more than a few cell fraction experiments images on immunoblots 
would fluctuate due to several possible causes.  Each cell fractionation experiment improved 
upon the last by adjusting technique to better control contamination. Along with technique 
adjustment there would also be an adjustment in antibody concentration during blotting if 
needed. Although controls started to improve throughout the runs, the common trend that could 
be seen on the blot was that genome edited DNMT1 was consistently present in all lanes 
including the mitochondrial fraction (Fig. 3-5) where the absence of DNMT1 was critical for 
validation. The near absence of H3K4me3 in the mitochondrial fraction with the expression of 
DNMT1 in all three lanes initiated a reinvestigation and revalidation of sequences for the 
genome edited cell lines.  
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Figure 3-5. Detection of DNMT1 in all sample lanes. Immunoblot investigating expression of 
DNMT1 found at 185kD. Cellular fractionation provided whole-cell lysate, cytosolic and 
mitochondrial fractions to be probed. VDAC is a loading control found only in whole-cell and 
mitochondrial fractions. Tubulin is a nuclear and cytosolic contamination control that should not 
be present in the mitochondria. H3K4me3 is a nuclear contamination control that should only be 
found in whole-cell lysate. The presence of DNMT1 in mitochondrial lysates from the two 
genome edited cell lines suggests that residual targeting activity remains despite successful 
genomic editing.  
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Reinvestigation of DNMT1 genome edited sequences uncovers a novel frameshift.   
Primary investigation of possible CRISPR/Cas9 indels for HCT116 was performed by selecting 
sequences that had insertions or deletions in multiples of one or two base pairs, in order to disrupt the 
reading frame between ATG2 (mitochondrial start) and ATG3(nuclear start). Immunoblot analysis 
provided evidence that DNMT1 is still able to translocate into mitochondria, suggesting that either 
DNMT1 is able to translocate without a targeting sequence, as is apparently true for many nuclear 
encoded mitochondrial proteins, or that residual targeting sequence remains in the engineered locus.  
Translating the sequencing results shown in Fig. 3-4 does indeed show that from ATG2 and after the 
17bp deletion, a novel stop codon does arise; however, translation in the reverse direction from ATG3 
reveals inframe coding sequence past ATG2 to a new ATG that is in frame with ATG3.  This sequence, 
while different from that of the original MTS of DNMT1, is evidently able to produce a partially 
functional MTS. Mitoprot II Software (calculates mitochondrial targeting probability) calculated that the 
two genome edited samples ( C6 and C8: deletions in multiples of two) selected for experimentation had 
a 27% chance for one and a 70% chance for the other to still be targeted to the mitochondria.  
Rescreening and selection of genome edited cell line produces authentic novel stop codon.                                                    
Genome edited cell lines were rescreened by previously mentioned methods and sequenced. 
Sequencing (Fig. 3-6) (19bp del)  revealed several clones that had a deletion of n amino acids plus one 
base pair for both HCT genome edited and 3BKO genome edited cell lines.  These deletions produced 
novel stop codons in the MTS region. Two clones from each cell line were selected; sequences were 
translated upstream from ATG3 and analyzed as above for the presence of an engineered new upstream 
ATG.  These sequences were analyzed using Mitoprot II; each cell line resulted in a less than 2-3% 
chance of possessing a functional MTS and no new ATG with their edited sequences (Table 3-1).  
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Figure 3-6. Sequence illustration of wild-type and genome edited cell lines. Sequences are 
represented as: intron 1 (blue lower case) with ATG1 and ATG 2(blue oval), new ATG (yellow), 
mitochondrial targeting sequence (upper case red), ATG3 (green oval), Exon 1 (upper case 
green), gRNA (underlined red), novel stop (red oval). WT (wild-type) illustrating two ATGs 
inframe with nuclear ATG3 with location of gRNA. 17bp del illustrates altered sequence with 
ATG1,2 inframe with novel stop; new ATG now inframe with ATG3. 19bp del illustrates altered 
sequence with ATG1,2 inframe with novel stop; no ATG inframe with ATG3, presumably non-
functional MTS.  
 
 
46 
 
 
 
 
 
 
 
 
 
 
 
Table 3-1: Specification of clone mutation, outcome and probability of processing a functional 
mitochondrial targeting sequence.  
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Figure 3-7. Immunoblot analysis for DNMT1 expression of select genome edited cell lines.  
Lane 1, Dual Color Plus Ladder: lanes 2-4, HCT116 wild-type: lanes 5-7, HCT genome edited 
clone A7: lanes 8-10, 3BKO: lanes 11-13, 3BKO genome edited clone B3. Expression for 
DNMT1 at 185kD in all lanes although at a reduced level in fractions that have had the MTS 
deleted. WCL (whole cell lysate), CYTO (cytosolic fraction) and MITO (mitochondrial fraction). 
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Immunoblot comparative analysis of DNMT1 revealed a reduction in expression levels.  
Immunoblotting was performed on all selectively screened cell lines as well as HCT116 
wild-type to determine DNMT1 expression (Fig. 3-7). Previous studies with an analogous 
DNMT1 antibody have shown DNMT1 expression in HCT116 cells. These current results 
suggest the same expression of mtDNMT1 in HCT116 wild-type and 3BKO; however, in the 
genome edited cell lines there is not a complete loss of expression as predicted. In the HCT 
genome edited and the 3BKO genome edited cell lines the expression of DNMT1 has been 
significantly reduced.  
Immunoblot analysis for the expression of DNMT3B may be more complicated than 
expected.  
 Immunoblot analysis for DNMT3B was performed using three different monoclonal 
antibodies (Fig. 3-8). The antibodies bound in similar regions so expression was predicted to be 
comparable. Western blots provided on manufacturer’s website (Santa Cruz) place DNMT3B 
protein anywhere from 80kD-130kD (97.5kD predicted) with identical antibodies, however there 
is no report of DNMT3b in the mitochondrial fraction for this cell line. Immunoblot analysis of 
the tested antibodies was variable and inconsistent. Between the three blots, DNMT3B 
immunoreactivity indicates heterogeneity of size, and further analysis with other methods will be 
necessary to make a definite account of DNMT3B. For each antibody, we expected to see bands 
in HCT 116 wt and genome edited cell lines (WCL, cytosol and mitochondrial lysate) that were 
absent from 3BKO and its genome edited derivatives.  For anti-DNMT3B-F2 antibody (Fig 8-
3A), WCL bands at >80kDa are absent from 3BKO lysates, but there is no definite band in the 
mitochondrial fraction for any of these cell line. For antibody D1, 50kDa bands in mitochondrial 
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extracts of HCT116 wt and derivatives are absent from 3BKO and its derivatives, but no 
convincing and consistent bands are apparent in WCL (Fig 8-3B).  Bands produced by antibody 
G1 are present in all 4 lines (Fig 8-3C).  Interestingly this antibody (Fig. 3-8 C) produced bands 
in mitochondrial lysates at 37kD and ~60kD, which might represent a cleaved DNMT3B 
product.  Again, these bands are present across all 4 lines.  These data raised concerns that the 
3BKO cell line obtained from Dr. Vogelstein at Johns Hopkins might have been contaminated 
with a wt line 
Genotyping of 3BKO cell line validates original knock-out.  
 The genotype of the 3BKO cell line can be identified by wild-type specific (R2) and 
mutation specific primers (R21) (IDT) (illustration in Fig. 3-9A) for PCR (performed identical as 
formerly mentioned PCR methods). PCR agarose gel images (Fig. 3-9B) in HCT116 wild-type 
do not produce a product for the in silico knockout sequence but do demonstrate a product for 
the reverse primers in exon2 indicating an unmodified wildtype cell line with the absence of a 
knock-out. In the same gel image the 3BKO cell line does not produce a product for reverse 
primers in exon2 (R2) but do demonstrate a product for the reverse primers in exon21 (R21) that 
create an in silico sequence indicating that there is an apparent knock-out.  
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Figure 3-8. Immunoblot analysis of DNMT3B. Lane 1, Dual Color Plus Ladder: lanes 2-4, 
HCT116 wild-type: lanes 5-7, HCT genome edited clone B4: lanes 8-10, 3BKO: lanes 11-13, 
3BKO genome edited clone B3. Protein lysates for all blots were from same cellular 
fractionation preparation and all protein amounts are consistent. H3K4me3 was run at the bottom 
of each blot for contamination control. Blots A-C are DNMT3B F2, D1 and G9 antibodies 
(suppliers?) respectively. 
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Figure 3-9A: Diagram of expected product of wild-type and 3BKO from PCR. WT 
illustrates the expected fragments (double-sided arrow) of a wild-type cell line. The reverse 
primers (R2) that lay in exon 2 will be able to make an estimated ~800-1000bp fragment with 
forward primers (F1,2,3) in exon 1; since exons 2-21 are present the fragment will be too large to 
produce for reverse primers (R21) after exon 21 to meet up with forward primers out of exon 1. 
3BKO illustrates that when exons 2-21 are knocked out (red hatching) that only reverse 21 
primers with in silico sequence will be able to produce a fragment (estimated 2-3kb) with 
forward primers with in silico sequence.  
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Figure 3-9B. DNMT3B genotyping PCR experiment. Lane 1, 1kb+ ladder: lanes 2-7, HCT 
wild-type samples with indicated forward and reverse primers: lane 8, negative control: lanes 10-
15, 3BKO samples with indicated forward and reverse primers. Visible bands in HCT wild-type 
and 3BKO are indicative of a positive DNMT3B knock-out.  
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RTqPCR shows decreased transcription among genome edited cell lines. 
 RT-qPCR was carried out on strand-specific cDNA of HCT116 wild-type and 
genome edited cell lines. Primers for 16s RNA, ND6, Cox1 and ND1 were chosen to 
assess the effect of altering mtDNMT1 levels on transcription in the genome edited cell 
lines. Using total cDNA synthesized by reverse transcription with random hexamers, the 
expression levels were normalized to the geometric mean of values for beta-Actin and 
GAPDH.  
 Genome editing in the HCT116 wt background indicates modest changes in 
transcription.  We observed a minimal reduction in transcription of 16S rRNA (heavy 
strand) from wild-type in the genome edited lines (Fig 3-10). ND1 and Cox1, two protein 
coding heavy strand genes, and ND6, the only protein coding region on the light strand, 
each show a 20-40% reduction in the HCT genome edited lines.  In contrast, deletion of 
DNMT3B reduces transcription in the protein coding regions analyzed by 2-fold; removal 
of the DNMT1 MTS did not significantly change this reduced transcription.  
 
 
 
 
 
 
 
55 
 
 
 
 
 
Figure 3-10. Mitochondrial Transcription of genome edited cell lines. Bar graph 
characterizes real time RT-PCR analysis of mitochondrial genes in HCT116 and 3BKO cell 
lines. The y-axis signifies normalized mRNA expression to the geometric mean of values for -
Actin and GAPDH.  
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Quantification of 5-methylcytosine in genome edited cell lines by means of MeDIP. 
 Since expression of DNMT1 was detected in mitochondrial fractions of the genome 
edited cell lines at varying levels, and since DNMT3B knockout had a profound effect on 
mitochondrial transcription, it was important to determine the levels of 5mC in the cell lines to 
determine whether 5mC levels might be related to the levels of transcription. DNA was purified, 
sheared to a length of 200-500bp and checked on an agarose gel according to protocol (Fig. 3-
11). Challenges occurred when purifying DNA and trying to retain enough to proceed through 
the IP; after several trouble-shooting experiments, it was concluded that the best way to purify 
DNA with phenol-chloroform was to use a freshly prepared mixture. The phenol-chloroform 
must have the right acidity for the DNA to precipitate into the organic phase while the less 
neutralized RNA remains in the aqueous phase.  As well, an RNase treatment step was not 
original to the protocol; however, after low levels of DNA were observed on analytical gels after 
sonication, it was thought that RNA might be compromising nanodrop readings. After the RNase 
treatment step was added the 260/230 ratios significantly improved on the nanodrop, indicating 
previous unwanted RNA was altering projected DNA quantities.  
After MeDIP and a final round of DNA purification, an endpoint PCR was performed to 
visualize how wild-type and genome edited samples differed by band intensity in regards to 
specific antibody on an agarose gel. The endpoint PCR was also utilized to see if levels of 5mc 
could be roughly quantified by comparing band intensity to a non-specific IgG control.  Several 
commercial preparations of IgG yielded a very high background, in many cases higher than the 
signal obtained with 5mC, and we performed tests on multiple IgG preparations from different 
suppliers.   
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Figure 3-11. Sonication of HCT wild-type and genome edited cell lines. Lane 1: 1Kb Plus 
DNA Ladder, lanes 2-7: unsonicated samples, lanes 8-13: 15 minutes of 30 seconds on 30 
seconds off high power sonication, lanes 14-19: second round of identical sonication. 200-800 
base pair smear in last six lanes indicate proper shearing.  
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Figure 3-12. Endpoint PCR of HCT116 wild-type and genome edited cell lines. Top segment 
of the agarose gel is that of the immunoprecipitated samples; each cell line is denoted at the top 
of figure and lanes of cell line are lined up by IgG, 5mc and 5hmc antibodies respectively. 
Bottom segment of the gel is the concurrent input samples; even band intensity in this portion 
indicates and equal amount of DNA went into the IP.  
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The IgG from Millipore gave a baseline level appropriate to move forward to qPCR seen by a 
higher band intensity in all IP lanes over IgG (Fig. 3-12). 
 Quantitative PCR was performed on all DNA samples from the MeDIP using mitochondrial 
primers for HSP1, LSP and 16s rRNA, and the outcome of the assay was formulated in excel and 
graphed. The first set of primers evaluated detected HSP1 (Fig 3-13); in comparison to wt HCT116 
cells, the levels of 5mC in mtDNA decreased ~25% in HCT-GE cells, 60% in 3BKO cells and 75% 
in3BKO-GE cells.  This data is in accord with the transcription data shown in Fig 3-10, supporting 
our hypothesis that reduced 5mC results in increased mitochondrial transcription.  Subsequent 
qPCR analysis of LSP and 16s regions, however, showed a different pattern; both LSP and 16s 
amplicons demonstrated an increase This data contradicts all other evidence from the Taylor lab and 
from other published works which all point to a role for both DNMT1 and DNMT3B in mtDNA 
methylation, and a controlling role in mtDNA transcription from both HSP and LSP.  Furthermore, 
the qPCR data did not agree with the endpoint PCR.  A closer look at the raw data from the qPCR 
reveled inconsistencies in the readings for input samples.  Since 4ug DNA are used for each IP, and 
the amount of DNA precipitated is very small, we use the IP supernatants as a measure of input for 
each sample.  We expect each input sample qPCR reading to be very similar, and from prior 
experimentation find this to be true.  However, in the experiment shown in Fig 3-13, input samples 
were inconsistent from experiment to experiment and varied by as much as 5-fold in some cases. A 
fault in the protocol used for the process of sonication was brought to our attention after these 
findings; total purified DNA was sonicated and then the concentration was adjusted, when in fact 
varying concentrations of DNA as well as total volume going into sonication affects the outcome of 
shearing.  
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Figure 3-13: Quantification of 5mc from MeDIP.  Immunoprecipitated and input DNA was 
examined by qPCR with mitochondrial primers for HSP, LSP and 16S rRNA. Levels of 5-methyl 
cytosine are depicted relative to input for each cell line. Data represents average of triplicate 
readings ± SE. HCT GE clone B4, 3BKO GE clone B3. 
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As a result, we began a new IP experiment in which we adjusted the concentration of 
DNA to equivalent totals prior to sonication. All steps after sonication were taken according to 
protocol leading into qPCR; again, results for this assay were highly variable and a reason for the 
variability in outcome was provisionally inaccessible. The importance of this assay in 
determining the role of methylation in the mitochondria resulted in a large amount of effort in 
troubleshooting the source of variability in this data; efforts were made in procurement of fresh 
buffers and reagents, constructing all new primers for qPCR, quantitating and adjusting sonicated 
DNA prior to IP, performing qPCR assay on different equipment, using several different 
amplification reagents in qPCR, obtaining new antibodies for IP and attempting to formulate 
results independently from IgG.  These efforts resulted in the same unusable results.  
 At this point, a possible malfunction in the sonicator was brought to our attention by a 
colleague.  Finally, we determined that the faulty sonicator was shearing the DNA into 
exceedingly minute fragments and this outcome appeared to vary from sample to sample.  These 
small fragments would be unable to act as template in qPCR reactions. Results of a sonication 
assay (Fig. 3-14A) where HCT116 wild-type and HCT genome edited samples were of equal 
concentrations and volume and processed through two separate sonication apparatuses (one out-
of-lab new instrument and the one in-lab old instrument) revealed significant differences. 
Following the original sonication protocol we used two 15 minutes rounds of sonication on high 
with 30 seconds on and 30 seconds off. Samples were withdrawn for analysis by agarose gel 
electrophoresis after each round of sonication.  For the out-of-lab, new sonicator, both 
sonications produced bright, broad bands in the gel, ranging in size from 300-600bp with only 
slight visible smearing, consistent with optimum shearing. However, the older in-lab sonicator 
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showed a significant decrease in band intensity, even after a single round of sonication, 
suggestive of excessive DNA degradation. This decrease in band intensity can plausibly be 
explained by supposing that the in-lab sonicator is processing the samples at such a great force 
that the fragments it is producing are so minute they are running right through the agarose gel.  
Coincidently, results from another MeDIP came back irregular in an endpoint PCR. The 
usual protocol requires 35 cycles in the Thermocycler, however, bands of equal intensity both in 
the IP and Inputs were observed in the gel image (Fig 3-14B). The virtually equal intensity in the 
IP lanes for the gel was something that has not been observed before and needed to be 
investigated; the assay was run again at 25 cycles, in an attempt to get more semi-quantitative 
data. Upon reducing the cycle number the gel image for the assay (Fig 3-14C) revealed unequal 
amounts in the Input lane. These variances in Input are unacceptable to proceed to qPCR and 
possibly coincides with the sonication malfunction. Reinvestigation of the gel image for the 
sonication check for the corresponding MeDIP reveals what appears to be over shearing as well 
(Fig. 3-14D). 
As a result of these extensive quality checks, and the clear malfunction of our sonicator, 
which is used by all investigators in the Cancer Center, a new bath sonicator has been ordered for 
Massey Cancer Center.  Once it is in place, we plan to carry out the necessary replicate assays to 
allow publication of this data set. 
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Figure 3-14 A-D: Evidence for inconsistent qPCR results. A: Sonication assay reveals in-lab 
sonicator has sheared samples to such a small size that a 1% agarose gel cannot contain. First 
round sonication usually has smear of 500-1000bp, while second round sonication usually has 
smear of 200-700bp but not below. B: Endpoint PCR (35 cycles) with all input and IP samples 
from MeDIP on agarose gel. IP samples showing virtually equal band intensities, inconsistent 
with previous assays requiring further exploration. C: Endpoint PCR (25 cycles) with Input and 
IP samples; more sensitive assay reveals uneven loading of DNA going into the MeDIP (input). 
D: Sonication check of concurrent MeDIP reveals overlooked improper shearing of DNA.  
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Chapter 4: Discussion 
The mitochondrial targeting sequence for DNMT1 was discovered by the Taylor lab, and 
understanding the functional significance of the cytosine modifications that result necessitated 
disturbing the ability of the proteins responsible from entering the mitochondria. Preventing 
DNMT1 from being translocated to the mitochondria without affecting the nuclear protein was 
also a novel and ambitious undertaking.  Both HCT116 and 3BKO cell lines were able to have 
the mitochondrial targeting sequence of DNMT1 altered using CRISPR/Cas9 genome editing. 
Sequence authentication displays that the deletions created with the endonuclease generate a 
premature stop codon that disrupts the targeting peptide, further substantiated by mitochondrial 
targeting software. Efforts to test and create these clones were substantially drawn out because of 
unconventional and multiple ATP start sites. Within the case of multiple start sites it is important 
to not only examine for new downstream stop codons after the novel deletion but to also make 
sure that said deletion does not generate in-frame and functional new upstream start sites that 
were originally out of frame. These efforts are critical for a complete understanding of the 
potential outcomes when undertaking genome editing of unique DNA regions. 
The immunoblots of this study build upon previous lab work that suggest again that 
DNMT1 translocates to the mitochondria [22]. The expression levels of DNMT1 in the genome 
edited cell lines appears to be half of that in the lines that have complete MTSs (Fig. 3-7). This 
finding suggests that the MTS does carry DNMT1 to the mitochondria because it is in lanes of 
all samples.  However, these data suggest that the MTS it is not the sole contributor to DNMT1 
translocation.  The expression levels of DNMT1 in the genome edited cell lines suggest that 
making the MTS nonfunctional will affect the amount of DNMT1 going into the mitochondria 
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but does not yet answer any questions about the functional significance of the cytosine 
modifications resulting from mtDNMT1.  
Previous studies have shown that the MTS of DNMT1 possesses the capability of taking 
GFP to the mitochondria [22] and that when the MTS peptide comes in contact with the outer 
membrane of the mitochondria it is recognized and validated for import; that being said it is of 
importance to understand that there is always a possibility that DNMT1 uses alternative methods 
to translocate to the mitochondria. There are several proteins that translocate to the mitochondria 
without any obvious mitochondrial import signal.  These proteins are thought to translocate 
through interaction with chaperones which maintain an unfolded state [31]. However, although 
no studies to date have shown interaction of DNMT1 with chaperones, the idea of a chaperone 
complex shuttling DNMT1 to the mitochondria should not be out of the question. Most peptides 
imported into mitochondria are recognized by their N-terminal targeting sequences; however, it 
is also acknowledged that many precursors have internal recognition sequences [9]. The nature 
of these internal sequences have not been characterized largely because they lack consistent 
arrangements [9]; the possibility of DNMT1 also containing an internal targeting sequence has 
not been investigated.  
The argument over whether or not DNMT3B is taken to the mitochondria will still be 
debatable according to formerly presented blots. There has been only one published study where 
a western blot has shown DNMT3B in the mitochondrial fraction of a cell [16]. Blots from our 
current study are inconclusive. Each antibody used in this work yielded vastly different results 
despite the fact that each antibody recognized similar and overlapping regions of DNMT3B. 
Several publications and manufacturer datasheets using these antibodies show DNMT3B ranging 
in size from 80-130kD; the predicted molecular mass, based on amino acid sequence is 97.5kD. 
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Figure 3-8A displays strong bands in the whole-cell lysate and faint bands in cytosolic fractions 
at ~80kD in the HCT116 wt and the HCT genome edited cell lines; bands are absent in the 
3BKO models indicating that there is a true knock-out, however there is no signal in 
mitochondrial extracts, suggesting that DNMT3B does not get transported to the mitochondria to 
the extent detectable by immunoblot. Figure 3-8B displays the same size band as the previous 
figure however it is expressed in every sample and only in the whole-cell lysate fraction. If the 
80kD band truly represents DNMT3B, then its presence in the supposed 3BKO line indicates 
that this line is not a true knock-out. Interestingly there is a band at ~45kD expressed strongly in 
the mitochondrial fraction of both the HCT lines and faintly in the mitochondrial fraction of the 
3BKO lines. These results might indicate cleavage of DNMT3B during translocation into the 
mitochondria in the HCT lines, and possible DNMT3B contamination from cytosol resulting in 
the faint bands seen in the 3BKO mitochondrial extracts, perhaps due to improper technique. 
Figure 3-8C is just as unique as the first two blots; there is a band in the whole-cell lysate and 
cytosolic fractions of every sample at ~100kD that could be DNMT3B. Again, in the 
mitochondrial fraction there is a band that could represent cleavage of DNMT3B in the import 
complexes of the mitochondria at ~40kD; however Figure 3-8C displays these bands in every 
sample. Several of these figures are suggestive that there is not a true knock-out of DNMT3B; 
thus our genotyping experiment was crucial to characterization of this line before proceeding on 
to other characterization experiments. Verification of a knock-out was attained (Fig. 3-9) 
meaning that any interpretation from the immunoblots would be difficult to substantiate.  
DNMT3B does not contain an N-terminal MTS as found for DNMT1. An internal 
targeting sequence has not been found within DNMT3B, therefore transport to the mitochondria 
or recognition of the protein at the outer membrane is questionable. N-terminal targeting 
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sequences are predominantly cleaved on passage through the outer membrane [31], and, for 
many proteins, multiple cleavage events occur along the length of the peptide upon passage 
through the inner mitochondrial membrane. The purpose of these proteolytic cleavage events that 
occur throughout the import complexes has not been identified, although some proteins have 
been characterized to be cleaved at defined points to specific sizes once inside the mitochondrial 
matrix. Previous work in the Taylor lab has shown immunoblots of DNMT1 expression in the 
mitochondrial fraction [22]; however, there has been a consistent lower band that has not been 
characterized at ~60kD. The DNMT3B immunoblots of this study sometimes display lower 
bands as well in the mitochondrial fraction. It would be of significance to examine the lower 
bands in current and past studies with techniques such as mass spectrometry to better identify 
their relationship to the methyltransferases in the mitochondria.  
RTqPCR data was more accommodating to address the functional significance of DNA 
methyltransferases in the mitochondria. Across the three protein coding mitochondrial genes 
tested, ND1, Cox1 and ND6, there is an apparent trend towards reduced expression, correlating 
with genome editing of the MTS in mtDNMT1 alone or in conjunction with knockout of 
DNMT3B.  Our previously published work indicates that increased mtDNMT1 expression 
results in increased mitochondrial transcription [22], and ongoing in vitro experiments in our lab 
using a reconstituted system with recombinant enzymes and transcription factors, demonstrate a 
3-fold increase in transcription from HSP when the 3 CG dinucleotides in and around the 
promoter are methylated, in comparison to the unmethylated sequence. The 16s ribosomal RNA 
gene does not showcase this trend as the difference between samples is subtle.  The level of 
rRNA transcription is much higher than that of protein coding mRNAs, and rRNA transcription 
is believed to operate by a different mechanism that is independent of polycistronic ORF mRNA 
69 
 
production [32].  ND1, Cox1 and ND6 demonstrate a significant pattern of decline amongst the 
samples. In those gene sets when the MTS of DNMT1 has been genomically edited out of the 
HCT116 cell line there is an overall decrease in transcription of ~27%. The most significant 
decline in transcription occurs in the DNMT3B knock-out cell line, which has a decline in 
transcription of ~55%. Further editing of the DNMT1 MTS in this background did not further 
decrease the transcription level.  
The lack of significance in the difference between the genome edited 3BKO and the 
3BKO in itself could possibly mean that DNMT3B and not DNMT1 is the more functionally 
significant methyltransferase in the mitochondria. Previous studies have shown in the nucleus 
that in the absence of DNMT1, DNMT3B expression increases in the absence of the DNMT1 
[30]. This could possibly be the same case in the mitochondria and explain that in the genome 
edited cell lines the reduction in transcription is only 27% and not closer to 50%; that DNMT3B 
is making up for some of the absence of DNMT1. This is possibly evident in (Fig 3-8) where one 
can see a greater expression level of DNMT3B in the HCT genome edited cell line over the 
HCT116 wild-type.  
Endpoint PCR has been a standard checkpoint throughout multiple investigations in the 
Taylor Lab and many other labs. The agarose gel image from endpoint PCR gives a basic 
measurement of success from the MeDIP; however, this assay needs to be closely scrutinized as 
a lower cycle number reaction can reveal discrepancies obscured with a higher cycle number, as 
shown in this research. It would be essential to optimize this assay in conjunction with the 
MeDIP before placing any value on the reliability as a checkpoint.  
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QPCR was planned to be an essential assay in this research for measuring how genomic 
modifications to methyltransferases affect levels of methylation within mitochondrial DNA. As 
results proved to be highly variable, we do not yet have the necessary number of replicates for 
conclusive support of our hypothesis.  The principle effort of having equivalent amounts of DNA 
going into the MeDIP is critical in order to have reliable qPCR data. However, we were able to 
pinpoint the source of error, in the faulty sonicator. The troubleshooting to find this equipment 
failure, although prolonged, did not go to waste; the protocol for the MeDIP was shortened and 
made to be more efficient and precise, and the technical experience gained was invaluable. 
Replacement of the faulty equipment should allow future experiments to complete this study for 
publication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
 
 
Chapter 5: Perspectives and Conclusions 
 There is continued controversy in the literature concerning which methyltransferases 
reside in the mitochondrial matrix, largely generated because different investigators use different 
antibodies with largely differing sensitivities.  We chose a more specific genetic approach in 
order to avoid issues of antibody detection.  
The goals of this study were therefore to define which methyltransferases were present in 
mammalian mitochondria and to gain understanding of the role and functional significance of 
mitochondrial DNA methylation.  We approached this study using CRISPR-Cas9, the new and 
cutting-edge technology for genome editing to remove the MTS from DNMT1, thus minimizing 
effects on nuclear cytosine methylation, while impacting mitochondrial modification.  This same 
approach is not possible with either DNMT3a or 3b, because they lack N-terminal MTS.  Our 
expectation was that depletion of mtDNMT1 would result in reduced cytosine methylation along 
with reduced transcription.  
 To our surprise, removal of the DNMT1 MTS did not completely prevent the 
localization of this enzyme to the mitochondria, raising the possibility that the enzyme can 
translocate to this organelle using alternative mechanisms.  Significantly reduced protein 
expression of the cell lines without a DNMT1 MTS conceivably emphasize the cellular 
importance of necessitating DNMT1 to be in the mitochondria; however, the transcription data 
presented here supports the notion that other methyltransferases besides DNMT1 localize to 
mitochondria and may be ever more functionally significant. Deletion of the MTS in DNMT1 
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shows only a meek reduction in transcription, not until removal of DNMT3B do we see a two-
fold decrease in transcription from mitochondrial protein coding genes. As well, no significant 
reduction in transcription occurred when the DNMT3B knockout also lost the MTS of DNMT1; 
apparently, contrary to what we expected, DNMT3B is being evidenced to big a bigger player in 
mitochondrial transcription.  
 DNMT3B appears to be an attention-grabbing target to further explore. Investigation into 
possible processing of DNMT3B upon entering the mitochondria is evidenced by this works 
immunoblots, could lead to the further convincing proof that DNMT3B is translocated to the 
mitochondria. Not only could research define translocation, it could very well point towards the 
mechanism of translocation. An understanding if and/or where DNMT3B is being cleaved might 
expose some internal targeting sequence that could be referenced with other different proteins 
that have not been able to be exposed in the mitochondria.    
 As an orthogonal approach to quantifying functional significance of DNA 
methyltransferases to under-methylated mtDNA, the Taylor Lab has developed a completely 
methylated representation; accomplished by M.Sss1 which is a CpG methyltransferase that will 
methylate all CpGs. Since methylation in the mitochondria is known to be exceptionally low 
compared to the nuclear genome, this over-methylation approach may give a more true 
quantification. The Taylor Lab has humanized codon usage and placed the TFAM MTS at the N-
terminus of M.Sss1. We found that constitutive overexpression is non-permissive since we were 
not originally able to obtain stable clones. The Taylor Lab has now developed an inducible 
construct of M.Sss1 and have begun to test its effect on mtDNA methylation and mitochondrial 
transcription. As well, current investigation suggest that genome edited cell lines have 
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differences in mtDNA copy number average compared to that of wild-type. Lab efforts have 
begun to address the consistency of such differences and the most effective way to normalize 
them.   
Further effort will be necessary to conclude what mechanisms in the mitochondria are at 
work. To really comprehend the impact of mtDNA methylation it will be critical to classify all of 
the contributors involved and understand the mechanistic complexities that accompany cause and 
consequence of epigenetic modifications.  Genomic editing will significantly support the journey 
to understanding of epigenetics of the mitochondrion. Mitochondria have been implicated in a 
variety of neurodegenerative disorders and cancers and the lingering question of what is the 
plausible biological function of methylation in the mitochondria needs to be answered.  
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